Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.60 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523104 | 0.89 | LPAR3 (0.62) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL1657226 | 0.87 | LPAR3 (0.59) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL521934 | 0.87 | PIN1 (0.70) | LPAR3LPAR1PIN1PIN4AKR1B1 | |
| SCHEMBL1655971 | 0.85 | LPAR1 (0.58) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL1655670 | 0.82 | PIN1 (0.53) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL522944 | 0.80 | PIN1 (0.68) | LPAR3LPAR1PIN1PIN4ALDH1A1 | |
| SCHEMBL1658890 | 0.79 | LPAR3 (0.50) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL1659129 | 0.79 | LPAR1 (0.50) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL1657035 | 0.79 | LPAR3 (0.50) | LPAR3LPAR1PIN1PIN4TDP1 | |
| SCHEMBL526001 | 0.79 | KMT2A (0.65) | LPAR3LPAR1PIN1PIN4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8759373-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2476669-A1 | Cyanoisoquinoline compounds and methods of use thereof | Fibrogen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2044028-B1 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | FIBROGEN, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7928120-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | LPAR3 3272/4885LPAR1 3708/4885PIN1 912/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | LPAR3 3295/4885LPAR1 3790/4885PIN1 654/4885 |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | LPAR3 3295/4885LPAR1 3790/4885PIN1 654/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | LPAR3 3295/4885LPAR1 3790/4885PIN1 654/4885 |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | HIF1AN, HIF1A, EGLN3 | LPAR3 3295/4885LPAR1 3790/4885PIN1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.